Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

218.10 -1.10 (-0.50%)
Streaming Delayed Price Updated: 10:18 AM EDT, Aug 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
3 Pharma Stocks That Could See a Surge in Demand in 2023 ↗
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
News headline image
How To Attend Alnylam Pharmaceuticals Q1 2023 Earnings Conference Call ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,100 Today ↗
 
Via Benzinga
News headline image
Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' ↗
SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy... 
Via Benzinga
News headline image
A Bearish Sign Appears On Alnylam Pharmaceuticals's Chart ↗
 
Via Benzinga
News headline image
Here's How Much $100 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Analyst Ratings for Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Analyst Ratings for Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗
 
Via Benzinga
News headline image
3 Growth Stocks That Could Disrupt the Healthcare Industry ↗
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
News headline image
Looking Into Alnylam Pharmaceuticals's Recent Short Interest ↗
Alnylam Pharmaceuticals's (NASDAQ:ALNY) short percent of float has fallen 5.3% since its last report. The company recently reported that it has 5.10 million shares sold short, which is 4.82% of all... 
Via Benzinga
News headline image
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023 ↗
 
Via Benzinga
News headline image
Five Best And Worst Performing Healthcare Stocks In December 2022 ↗
Multiple factors are expected to help the healthcare industry overcome inflationary pressures. If you are looking to invest in this sector, then to help you select, here are the five best and worst... 
Via Talk Markets
News headline image
3 Growth Stocks That Could Rocket Higher in 2023 ↗
Upcoming binary events could push these stocks to new all-time highs. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 ↗
 
Via Benzinga
News headline image
Meta To Rally Over 29%? Here Are 10 Other Price Target Changes For Friday ↗
 
Via Benzinga
News headline image
Pfizer, BioNTech Fire Back At Moderna Over COVID-19 Vaccine Related Patent Claims ↗
 
Via Benzinga
News headline image
Looking Into Alnylam Pharmaceuticals's Return On Capital Employed ↗
Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q3 sales of $264.31 million. Earnings fell to a loss of $405.92 million, resulting in a 46.33% decrease from last quarter. 
Via Benzinga
News headline image
What 11 Analyst Ratings Have To Say About Alnylam Pharmaceuticals ↗
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
News headline image
Alnylam Scraps Interim Analysis For Heart Disease Trial, Rethinks Plans For Another Rare Disorder Program ↗
 
Via Benzinga
News headline image
Alnylam Pharmaceuticals: Q3 Earnings Insights ↗
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q3 earnings results on Thursday, October 27, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures? ↗
Despite enthusiasm in some camps, the risk of potential cures clouds market projections. 
Via Investor's Business Daily
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: 
Via Benzinga
News headline image
Roblox To $51? Plus Deutsche Bank Slashes PT On Deere & Company ↗
  
Via Benzinga
News headline image
3 Top Biotech Stocks Defying the Bear Market ↗
Bear market, shmear market. These biotech stocks are soaring despite the market downturn. 
Via The Motley Fool
News headline image
Where Alnylam Pharmaceuticals Stands With Analysts ↗
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.